Mavacamten

Phase 3Completed

0 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Cardiomyopathy, Hypertrophic

Conditions

Cardiomyopathy, Hypertrophic

Trial Timeline

Dec 14, 2022 → Oct 20, 2025

NCT ID

NCT05582395

About Mavacamten

Mavacamten is a phase 3 stage product being developed by Bristol Myers Squibb for Cardiomyopathy, Hypertrophic. The current trial status is completed. This product is registered under clinical trial identifier NCT05582395. Target conditions include Cardiomyopathy, Hypertrophic.

What happened to similar drugs?

7 of 20 similar drugs in Cardiomyopathy, Hypertrophic were approved

Approved (7) Terminated (1) Active (12)

✅Carvedilol + Metoprolol succinate + Metoprolol succinate + doxazosinAstraZenecaApproved

✅RanolazineGilead SciencesApproved

✅Ranexa + PlaceboGilead SciencesApproved

✅TafamidisPfizerApproved

✅MavacamtenBristol Myers SquibbApproved

✅AcoramidisBayerApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (19)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07361289	Pre-clinical	Recruiting	Jan 15, 2026	Aug 28, 2028	Hypertrophic Cardiomyopathy
NCT07004972	Approved	Recruiting	Sep 4, 2025	Dec 13, 2027	Symptomatic Obstructive Hypertrophic Cardiomyopathy
NCT07383025	Pre-clinical	Recruiting	May 21, 2025	Nov 30, 2029	Obstructive Hypertrophic Cardiomyopathy (oHCM)
NCT06146660	Pre-clinical	Recruiting	Jul 24, 2024	Nov 30, 2026	Obstructive Hypertrophic Cardiomyopathy
NCT06338202	Pre-clinical	Completed	Jun 24, 2024	Dec 19, 2024	Obstructive Hypertrophic Cardiomyopathy (oHCM)
NCT06551129	Pre-clinical	Recruiting	May 10, 2024	Jun 30, 2027	Obstructive Hypertrophic Cardiomyopathy
NCT06549608	Pre-clinical	Active	Apr 20, 2024	Apr 18, 2025	Hypertrophic Cardiomyopathy
NCT06112743	Approved	Active	Jan 24, 2024	Jul 9, 2026	Cardiomyopathy, Hypertrophic
NCT07107373	Pre-clinical	Active	Dec 22, 2023	Dec 31, 2025	Obstructive Hypertrophic Cardiomyopathy (oHCM)
NCT05939700	Pre-clinical	Recruiting	Nov 9, 2023	Apr 30, 2027	Breastfeeding
NCT06023186	Pre-clinical	Recruiting	Nov 3, 2023	Sep 30, 2026	Obstructive Hypertrophic Cardiomyopathy
NCT07168655	Pre-clinical	Completed	Feb 21, 2023	Mar 25, 2025	Obstructive Hypertrophic Cardiomyopathy (oHCM)
NCT05719805	Phase 1	Completed	Feb 20, 2023	Jul 25, 2023	Healthy Participants
NCT05582395	Phase 3	Completed	Dec 14, 2022	Oct 20, 2025	Cardiomyopathy, Hypertrophic
NCT05414175	Phase 3	Completed	Aug 19, 2022	Dec 11, 2025	Cardiomyopathy, Hypertrophic Obstructive
NCT05362045	Phase 1	Completed	May 16, 2022	Aug 19, 2022	Healthy Participants
NCT04766892	Phase 2	Completed	Mar 30, 2021	Feb 26, 2024	Heart Failure With Preserved Ejection Fraction
NCT03723655	Phase 2/3	Completed	Sep 27, 2018	Jan 16, 2026	Hypertrophic Cardiomyopathy
NCT03496168	Phase 2	Completed	Apr 26, 2018	Nov 9, 2023	Hypertrophic Cardiomyopathy

Competing Products

20 competing products in Cardiomyopathy, Hypertrophic

See all competitors

Product	Company	Stage	Hype Score
Tideglusib + Placebo	AMO Pharma	Phase 2	32
Mavacamten	LianBio	Phase 1	19
Mavacamten + Placebo	LianBio	Phase 3	30
CT-G20 + Placebo	Celltrion	Phase 1	21
Eplontersen + Placebo	AstraZeneca	Phase 3	44
Carvedilol + Metoprolol succinate + Metoprolol succinate + doxazosin	AstraZeneca	Approved	43
AZD0233 + AZD0233 Placebo	AstraZeneca	Phase 1	21
AZD4063	AstraZeneca	Phase 1	36
Eplontersen	AstraZeneca	Phase 3	47
Eplontersen + Placebo	AstraZeneca	Phase 3	44
candesartan	AstraZeneca	Phase 2	31
LCZ696 + Placebo	Novartis	Phase 2	35
Darbepoetin alfa	Amgen	Pre-clinical	26
Eleclazine + Placebo	Gilead Sciences	Phase 2/3	30
Ranolazine	Gilead Sciences	Approved	43
Ranexa + Placebo	Gilead Sciences	Approved	43
Ranolazine	Gilead Sciences	Pre-clinical	18
NNC6019-0001 + Placebo (NNC6019-0001)	Novo Nordisk	Phase 3	47
NNC6019-0001	Novo Nordisk	Phase 2	39
NNC6019-0001 + Placebo (NNC6019-0001)	Novo Nordisk	Phase 2	35